Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  ombrabulin
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-10 of 10 for your search:
Start Over
A Study of AVE8062 in Advanced-stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide Chemotherapies
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: EFC10145, EudraCT 2007-003592-39, NCT00699517
Trial of Ombrabulin (AVE8062) in Combination With Taxane and Platinum in Patients With Non-small Cell Lung Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: EFC10259, 2010-019384-11, U1111-1115-3677, NCT01263886
Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: EFC10260, 2010-024631-16, U1111-1118-5437, NCT01332656
AVE8062 in Combination With Platinum-taxane Doublet in Advanced Solid Tumor
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: TCD10620, EudraCT: 2007-006676-11, NCT00719524
Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 in Patients With Solid Tumors
Phase: Phase I
Type: Treatment
Status: Completed
Age: 20 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: TED10967, NCT00968916
Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Cisplatin in Patients With Solid Tumors
Phase: Phase I
Type: Treatment
Status: Completed
Age: 20 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: TCD11088, NCT01021150
A Study to Investigate the Disposition of Radio-labeled AVE8062 Compound Administered as a 30-minute IV Infusion to Patients With Advanced Solid Tumor
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BEX6587, 2008-007824-24, NCT01063946
Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel and Cisplatin in Patients With Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 20 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: TCD11089, U1111-1116-5905, NCT01095302
Dose-escalation, Safety, Pharmacokinetics Study of AVE8062 Combined With Bevacizumab in Patients With Advanced Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: TCD11379, 2009-017797-20, NCT01193595
A Dose-escalation Study of Ombrabulin in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 20 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: TCD11270, U1111-1115-2568, NCT01293630
Start Over